To model the cost-effectiveness of a biomarker-based approach to select patients for neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).
Introduction
Despite Level 1 Evidence [1] [2] [3] , adoption of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC) has been slow and rates of utilisation hover between 20% and 30% in the USA [4] . Randomised trials evaluating NAC in patients with T2-T4aN0M0 disease indicate an overall survival (OS) benefit, with a hazard ratio (HR) of 0.87 and absolute survival benefit of 5-10% [2, 3] . Beyond potential toxicity concerns, lack of utilisation is related to a perceived relatively low benefit and concern that many patients with organ-confined disease do not need additional treatment.
A predictive biomarker for response to NAC could avoid chemotherapy in those unlikely to respond and thereby expedite surgery and reduce cost and morbidity of NAC. Alternatively, selecting patients most likely to respond to NAC will enrich the population of patients receiving and benefiting from NAC. Several possible biomarkers have been described including mutations in DNA-repair genes ataxia telangiectasia mutated (ATM), retinoblastoma 1 (RB1), and Fanconi anaemia complementation group C (FANCC) [5] ; mutations in excision repair crosscomplementation group 2 (ERCC2) gene [6, 7] ; protein biomarkers [8] ; and RNA subtyping of bladder cancer [9, 10] . Although difficulties exist in assessing the potential risks and benefits of incorporating molecular markers into decision-making on the use of NAC, decision analysis modelling can improve our understanding of the efficacy and cost implications of using biomarkers to guide treatment. Furthermore, this model could serve as a basis for rational incorporation of emerging biomarkers into clinical decision-making for complex oncology. In the present study, we evaluated the cost-effectiveness of potential biomarkers to guide the use of NAC in patients with MIBC.
Patients and Methods
A decision analysis model was developed using TreeAge Pro 2016 to evaluate the cost-effectiveness of different management approaches in locally advanced MIBC (T2-T4aN0M0). All patients were assumed eligible for cisplatinbased NAC. There are three treatment arms in the model ( Fig. 1 ): (i) patients who undergo RC alone, (ii) patients who undergo unselected NAC followed by RC, and (iii) patients who undergo biomarker-directed NAC followed by RC. The primary endpoint was the cost-effectiveness of different approaches for use of NAC based on 5-year OS. Baseline assumptions in the model were varied by AE10% to generate CIs. One-and two-way sensitivity analyses were used to evaluate the impact of different assumptions on outcomes of the model.
Defining the Patient Population
The National Cancer Database (NCDB) was used to estimate proportion of clinical T2 (78.9%), T3 (13.7%), and T4 (7.7%) [4] . Survival data depends primarily on pathological stage and there is considerable discrepancy between clinical and pathological staging at the time of RC [11] . A multicentre study of 788 patients undergoing RC found pathological upstaging and downstaging occurred in 42% and 22%, respectively [11] . The stage distribution of patients undergoing RC for non-metastatic, MIBC was corrected for pathological staging (Table 1) .
Estimating Patient Survival
The 5-year OS of patients undergoing RC alone was obtained from several sources. The Southwest Oncology Group (SWOG) 8710 study found a 5-year OS for pT0 patients of 85% [1] and a cohort of >1 000 patients who underwent RC at the University of Southern California (USC) found 85% 5-year OS for node-negative patients with pT0, pTa, pTis [12] . In the same USC cohort, the 5-year OS for patients with pT1N0 was 76%, yielding an average 5-year OS of 81% for <pT2N0 [12] . The 5-year OS for stages pT2-T4 and pTanyN1-2 were obtained from a multicentre study of >2 700 RC cases [13] . (Table 1 ). Using this weighted-average approach, the 5-year OS for the entire cohort (cT2-T4) was 54.2%.
The survival benefit of NAC was estimated by a meta-analysis of 15 randomised clinical trials, which indicated a decreased risk of all-cause mortality associated with cisplatin-based NAC (HR 0.87; 95% CI, 0.79-0.96) [3] . This translates into 13% fewer deaths with a 5-year OS for NAC of 60.2% (if 100% of eligible patients receive NAC).
Treatment Assumptions
In the unselected NAC arm, the model was tested assuming all or just a portion of patients accept NAC. An NCDB analysis of patients with MIBC who underwent RC found that 20.9% received NAC in 2010 [4] . In some centres, NAC is only given in high-risk patients and the observed patterns of NAC utilisation probably reflect this risk-adopted approach [14] . We modelled a scenario of 20% of eligible patients receiving NAC. In the biomarker-directed NAC arm, all patients underwent biomarker testing. Those with a positive marker receive NAC and those with a negative marker receive RC alone. As current markers are not perfect in their prediction of response, not every patient with marker alterations (positive marker) benefits from chemotherapy. The percentage of responders based on prior clinical studies was incorporated into the model.
Biomarker Assumptions
For demonstrative purposes, we examined three potential biomarkers including genomic alterations in the DNArepair genes ATM, RB1, and FANCC [5] , missense mutations in ERCC2 [6] , and RNA subtypes of bladder cancer [9] .
In the study by Plimack et al. [5] , 22 of 58 patients (38%) had an alteration in ATM, RB1 or FANCC (biomarkerpositive). The rate of these mutations in The Cancer Genome Atlas (TCGA) was identical at 38.1% (ATM) 15.4%, RB1 21.1% and FANCC 1.6%) [15] [16] [17] . Of the 22 patients, 20 patients (91%) were ≤pT1N0 at time of RC.
Data on performance of ERCC2 were derived from a validation study by Liu et al. [6] , which revealed an ERCC2 mutation in 10 of 48 patients (21%). The rate in the TCGA for ERCC2 mutations was lower at 10.5% in a larger cohort, so this rate was used in the model [15] [16] [17] . Of the biomarker-positive patients, 80% were ≤pT1N0 at time of RC.
The impact of RNA subtyping on outcomes was based on an analysis by Choi et al. [9] . Basal, luminal, and p53-like subtypes constituted 32%, 33%, and 35% of the cohort and had a response to NAC (defined as ≤pT1N0) of 47%, 62%, and 6%, respectively. In the model, we assumed that patients with basal and luminal subtypes would receive NAC for an average response of 55.6% and those with p53-like tumours would proceed to RC alone. Based on a recent analysis suggesting limited benefit of NAC for luminal subtypes, we also performed a separate model wherein only patients with basal subtype tumours undergo NAC [10] .
A recent study found that patients who underwent NAC and were found to still have residual disease at RC had significantly worse 5-year recurrence-free survival (50% vs 63%; P = 0.01), cancer-specific survival (40% vs 59%; P = 0.003), and OS (33% vs 48%; P = 0.02) than pathologically stage-matched controls who underwent RC alone [18] . In the model, we similarly lowered OS in non-responders to biomarker-directed NAC by 31.25%.
Cost Assumptions
All patients were assumed to undergo RC. The average cost for RC and complications within 90 days was obtained from >7 000 RCs using Surveillance, Epidemiology, and End Results Program (SEER)-Medicare linked data and estimated at $33 000, including all Medicare and co-insurance reimbursement and patientliability costs [19] .
The costs for NAC and adjuvant chemotherapy were estimated at $10 500 for cisplatin-based regimens (gemcitabine/cisplatin or dose-dense methotrexate, vincristine, adriamycin, cisplatin) [20] . The cost of salvage therapy was complicated due to the recent approval of immune checkpoint inhibitors, for which there is insufficient cost data. A cost of $77 000 was estimated based on other biological regimens [21] . Patients receiving NAC and those with ≤pT2N0 were assumed to not receive adjuvant chemotherapy, whereas 30% of those with chemo-na€ ıve, non-organ confined disease were assumed to accept adjuvant chemotherapy. Similarly, 30% of those with non-organ confined disease were assumed to receive salvage chemotherapy. Whilst a recent report found that use of adjuvant chemotherapy was~20%, we used a higher rate as our model limited the use of adjuvant chemotherapy to patients with non-organ confined Estimated costs of dying from bladder cancer were abstracted from an analysis of SEER-Medicare linkage data [28] , which included all inpatient and outpatient claims among beneficiaries dying of bladder cancer made in the last-year of life [29] . Adjusted for inflation, the cost of dying from bladder cancer was estimated at $93 775.51 in 2017 USA dollars.
The cost of the marker was estimated at $2 000. Whilst the exact cost of sequencing varies between genetic tests; this was approximated between costs of commercially-available tests and the current cost of whole exome sequencing at our sequencing Core. This was modelled at varying costs and this cost will probably decrease over time.
Results
The results of the model are shown in Table 2 . The least effective strategy is RC alone with an average 5-year OS of 54.2% and mean survival of 2.71 years. For strategies of NAC before RC without a biomarker, 5-year OS is 60.2% if all get NAC and 55.4% if only 20% accept NAC. In the biomarker-based approaches, the 5-year OS was 56%, 59% and 62.8% for arms using ERCC2, RNA subtyping, and mutations in the DNA-repair genes ATM, RB1, and FANCC, respectively.
The overall cost of care was higher in arms that received NAC, in large part based on the proportion of patients who received NAC. The most expensive strategy was based on subtyping, as all had the cost of the marker and 65% had the added cost of chemotherapy. The most cost-effective strategy was based on DNA-repair genes ($31 482/life year). The least cost-effective strategy was based on RNA subtyping ($35 794/ life year). If NAC is only used in patients with basal subtype tumours, then the overall cost is $102 205 with an expected mean OS of 2.77 years and cost-effectiveness of $36 897/life year.
A tornado diagram was created to evaluate the impact of different factors on the cost of bladder cancer care (Fig. 2) . The cost of dying has the highest impact on the model due to the high cost of the last year of life and the significant mortality rate. Unsurprisingly, the cost of RC had a high impact. Finally, the probability of receiving and cost of salvage treatment were next most influential on overall cost, as salvage therapy ($77 000) is much more expensive than adjuvant chemotherapy ($10 500). As there are insufficient data on the likelihood of receiving salvage treatments, such as immune checkpoint blockade, we modelled the impact of 10%, 30%, 50% and 70% of patients receiving such therapies ( Table 3 ). The cost can vary by as much as $29 437 per patient. This has a greater impact on patients who do not receive NAC, as they are more likely to have non-organ confined disease and require salvage therapy.
A two-way sensitivity analysis was conducted over a wide range of biomarker-positivity rates and ability of the biomarker to predict response to NAC (Table 4) . If no patients have an abnormal marker (0%) then no NAC is given and outcomes are similar to RC alone. However, costs are $2 000 higher due to the cost of the marker. If 60% of patients have a positive marker and 60% of these patients have a response to NAC, the mean survival would be 2.99 years and the cost per patient would be $104 307. On the other hand, a marker that is positive in 20% of patients and predicts a response rate of 80% would have a mean survival of 2.89 years and cost of $98 793. [5, 6, 9] . Using biomarkers to enrich the response of patients undergoing NAC has the potential to increase the use of NAC in those patients most likely to respond and spare those unlikely to respond from potential toxicities associated with treatment.
In the present study, a decision analysis model was used to compare the cost-effectiveness of strategies using a biomarker 1 Variables with a wide bar indicate 'value sensitive' variables, suggesting they have a higher impact on cost in the model. For example, the cost of dying has the highest impact on the model. This is also why survival for pT2 has such a large impact, as higher mortality results in more cost.
2 The cost of RC had a high impact, as it impacts all patients.
3 The probability of getting and cost of salvage were the next most influential on overall cost, as salvage therapy ($77 000) is much more expensive than adjuvant chemotherapy ($10 500).
4 Variables that did not have a significant impact on cost in the model (not shown) included the probability of receipt of NAC (in the unselected NAC arm), probability of response to NAC, probability of biomarker positivity, accuracy of the biomarker, cost of the biomarker, probability of survival in patients who respond to NAC, and cost of surveillance after RC.
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© 2018 The Authors BJU International © 2018 BJU International to determine which patients should undergo NAC vs unselected use of NAC or RC alone. The most cost-effective strategy involved using DNA-repair genes, which provided NAC to 38% of patients with 91% response rate. While we recognise that further studies are necessary to define the optimal marker for selecting patients for NAC, there are many efforts underway such as the SWOG 1314 trial. Our present model is limited by the fact that the current literature still consists of small patient cohorts; however, the two-way sensitivity analysis we designed can predict the costeffectiveness of any marker based on its performance (Table 4) . One should also note that there are no direct comparisons of markers in the literature, so the best marker combination cannot be extrapolated from current literature and will likely evolve over time. More recent studies suggest that the basal subtype benefits more from NAC than the luminal subtype, with a suggestion that patients with luminal subtype tumours should undergo RC without NAC [10] . Further data are necessary to adequately model this type of information, as it is possible that NAC in some patients leads to worse outcomes due to a minimal benefit and delay in RC. Refinement in clinical staging may better define the optimal patient to treat with NAC, as it is known that patients with more advanced stage are more likely to benefit from NAC [10] . It is also possible that biomarkers will be beneficial in improving staging but this was beyond the scope of the present model [30] .
The major cost that impacted the model was cost of dying, which represents a significant proportion of total healthcare costs in the USA [31] . Strategies that improve OS benefit significantly by reducing the cost of dying and avoiding salvage therapies, which more than compensate for the upfront cost of NAC. Furthermore, the present study preceded the introduction of expensive treatments, e.g. immune checkpoint inhibitors, which will likely raise costs. The proportion of patients who required salvage therapies significantly impacted the cost of care with as much as a $29 437 difference in scenarios where 10% vs 70% of the patients with non-organ confined disease received salvage treatments.
The implications of the present study are significant. The use of NAC was found to be cost-superior to RC alone and strategies to enrich a population for responders is costeffective. While the best biomarker for response to NAC is not established, this type of modelling shows that even an imperfect biomarker can significantly improve costeffectiveness over unselected use of NAC. Furthermore, it is known that many eligible patients are not receiving NAC and that a biomarker for response may improve utilisation by selecting patients most likely to respond.
The model created is based on assumptions that are limited by the strength of evidence. Some evidence is strong, including the benefits of NAC and outcomes of patients with bladder cancer, which are rooted in large population data or randomised trials. Other assumptions, like the proportion of patients who will undergo adjuvant or salvage therapies, are not as well established. Furthermore, it is difficult to model the potential benefits on survival of salvage therapies but these benefits would be similar between different arms of the study and are unlikely to impact our results significantly. Finally, cost data are based on best available literature but can vary geographically and based on type of insurance. For the most part Medicare-based reimbursement was used, as it is the most widely used cost metric nationally even though some patients will be younger than 65 years and will have private insurance. Despite these limitations, we feel that the proposed model should be considered an example of how to estimate the value of novel biomarkers in oncological care.
Conclusion
A biomarker-based strategy using DNA-repair genes (ATM, RB1, FANCC) to identify which patients with MIBC should undergo NAC was more cost-effective than unselected use of NAC or RC alone. 
